

Oncology Today with Dr Neil Love: Key Presentations on Multiple Myeloma from Recent Major Oncology/Hematology Conferences

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. Talquetamab is a bispecific antibody targeting CD3 and which other protein?
 - a. BCMA
 - b. GPRC5D
 - c. CD20
 - d. CD19
2. What was the approximate hazard ratio for progression-free survival with ciltacabtagene autoleucel in the intention-to-treat population in the Phase III CARTITUDE-4 trial for patients with lenalidomide-refractory multiple myeloma (MM) who had previously received 1 to 3 prior lines of therapy?
 - a. 0.81
 - b. 0.64
 - c. 0.48
 - d. 0.26
3. Which of the following statements best describes the severity of most incidences of cytokine release syndrome (CRS) observed with linvoseltamab in the Phase II LINKER-MM1 study?
 - a. CRS was not observed
 - b. Most events were Grade 1
 - c. Most events were Grade 2
 - d. Most events were Grade 3 or 4
4. Subgroup analyses from the Phase III IKEMA and ICARIA-MM trials revealed a benefit with isatuximab-containing regimens among patients with which of the following subgroups of relapsed/refractory (R/R) MM?
 - a. Standard risk
 - b. Extended high risk
 - c. Ultra-high risk
 - d. Both a and b
 - e. All of a, b and c
5. What was the approximate reduction in the risk of disease progression or death reported with idecabtagene vicleucel in the overall population of patients with R/R MM after 2 to 4 previous regimens in the Phase III KarMMA-3 trial?
 - a. 21%
 - b. 35%
 - c. 51%
 - d. Greater than 70%